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Results. A signiﬁcant decrease in the value of the VAS due to swallowing was detected, after sublingual fentanyl administration.
After 4.5–5.5 weeks the difference reached on average 6 points in the VAS (p=0.001). In the clinical history of 49.18% of patients,
the beginning of pain relief was equal to/lower than 5min. After 10min in 73.77% of patients. Patient’s weight throughout the
study proved to be signiﬁcantly lower at all time points compared with baseline. Most prevalent adverse events were nausea
(42%) and constipation (39%).
Conclusions. Sublingual fentanyl probed to be efﬁcacious and fast acting, since there is a signiﬁcant decrease in the VAS at all
time points compared to baseline, and an important percentage of patients noticed pain relief in 5min or less.
http://dx.doi.org/10.1016/j.rpor.2013.03.582
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Introduction. The progressive incorporation of concomitant RT-CT in clinical practice, leads to increase side effects during and
after treatments. Pain is present in different clinical conditions: oral mucositis, esophagitis, urethritis, proctitis, radiodermatitis.
Objectives. The main objective of the study was to evaluate the intensity of breakthrough pain induced by cancer treatments
including radiation therapy, alone or associated with chemotherapy. As a secondary objective was to assess the efﬁcacy of
breakthrough pain treatments used.
Materials and methods. Retrospective observational study in 110 patients. Inclusion criteria were: outpatients over 18 years, with a
diagnosis of cancer at any site, regardless of stage, treated with RT or RT/QT. Patients were suffering severe breakthrough induced
by treatments with or without medication prescribed, and intensity using VAS was >6 in the last 24–48h.
Results. 67.3% of patients were male and 32.7% female. Mean age was 63 years. Breakthrough pain was produced by ‘mucositis’
(55.2%), followed by ‘esophagitis’ and ‘other’ (17.7% and 16.7% respectively). In the VAS, there was a decrease in the values as
the study progressed (control0 = 6 vs. Control3 = 3). We found signiﬁcant differences in all controls compared to baseline values
(p-value<0.0001).
Conclusions. Breakthrough pain induced by RT or RT/QT is a prevalent problem in the radiotherapy departments, mucosal inﬂam-
mation is the main cause of this pain. Transdermal fentanyl is the most frequent medication for baseline pain control. Results
show the efﬁcacy of the treatment of breakthrough pain induced by RT or RT/QT with sublingual fentanyl, since there is a signif-
icant decrease in VAS compared to baseline. Treatment satisfaction was rated good or excellent by 85.3% of patients and 92.7%
of physicians.
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Introduction. The acute esophagitis (AE) is one of the most important adverse effects of the radio chemotherapy (RQT) in lung
cancer, most of all if it’s perform concurring and the RT fractionated. Data published don’t allow to formulate exact recommen-
dations not dosimetrics nor therapeutics and it doesn’t exist a demonstrated effective prevention. The intranasal fentanyl with
pectin (INFP) is indicated in the oncological irruptive pain. It holds a great quickness of action and bioavailability and also avoids
the oral way.
Objectives. Evaluate the effectiveness of the INFP administrated in a precocious way in the regulation of the esophagitis in patients
with concurrent RQT for CPNCP III A–III B and CPCP-EL.
Method. Of all patients included in the study, it was calculated the probability of esophagitis G3-4 using a nomogram published
by Dehing–Oberige in 2010. In patients with a higher risk level analgesia was initiated in an early manner (EVA=0>3), combin-
ing transdermic fentanyl and INFP, to avoid the adverse effects due to swift escalade of opiods. The entitlement of INFP was
accomplished systematically in the nursing consulting room.
Results. After having treated the ﬁrst twelve patients, with a 2 months minimum follow-up process, the preliminaries results
are: the 75% were CPNCP III A–III B and the 25% CPCP-EL. Dose of RT 66Gy and 45Gy (2 f/day) respectively and the chemotherapy
CDDP-docetaxel andCDDP-VP16. The average dose of RTwhenesophagitiswas detected: 40′8Gy. Thepeak esophagitis (CTCAEv4),
G2:8p, G3:4p. Measured pain by EVA scale: average 6.1. Average dose of transdermic fentanyl 30g/h/72h. Average dose of INFP:
4g/h. There were not produced an interruption of the treatment in two patients, it was not possible to keep the oral ingestion.
The adverse effects were poor and slight (they will be speciﬁed in the congress).
Conclusions. These preliminaries data suggest that the intranasal fentanyl with pectin is efﬁcacious for the regulation of the pain
in the AE by RQT. The early start and the systemic entitlement in the nursing consulting room make for the accomplishment
